MC1R and melanoma: Significantly, we reveal that MC1R de-palmitoylation is catalyzed by APT2 and consequently ML349, an APT2 inhibitor, rescues defects in MC1R RHC variant signaling and offers a potential avenue to an effective melanoma prevention strategy.